The deadline for submission of abstracts has now been extended!

We are now accepting abstracts up until Monday 24th June via email. Once you have submitted, you will receive an email acknowledgement to confirm that your abstract has been received. You will then be contacted to confirm whether or not you have been selected to present a poster. Conference attendees are invited to be part of the programme by submitting abstracts for poster presentation. The abstracts will be evaluated anonymously by a panel of experts and prizes will be given to those judged to be outstanding.

Abstracts detailing Phase I clinical trials or any research aligned to these will be considered for acceptance.

Submission of abstracts associated with the focus areas of the conference is particularly encouraged:

  • Radiotherapy Combination studies
  • Novel targets and their impacts on trial designs
  • Immuno-oncology
  • Precision Medicine
  • Advanced Therapies
  • Trial Design Methodology

The abstracts summarising your research should be no more than 300 words and submitted in Word format with the names and affiliations of all authors. Abstracts presented at other conferences and events are welcome. 

Abstract guidelines are outlined below:

  • The title should be concise as possible. Please note that the title may be edited for conciseness.
  • All authors must be listed including full names, affiliations, and locations (including country).  Do not include professional titles, credentials, or addresses.
  • If authors have more than one affiliation, each affiliation should be numbered in order using superscripts. Do not list more than one affiliation per number. 
  • Word count should not exceed 300 words (excluding the title and author list).
  • The abstract should be structured with the following headings (in bold): Objective, Methods, Results, Conclusion.
  • Abbreviations should be defined at first mention.
  • Avoid citing references in the abstract.
  • Tables and figures should be avoided unless they truly add value to the abstract. If absolutely necessary, tables and/or figures must meet the following guidelines:
  • Tables must be in an editable format (word or excel file).
  • Table size must not exceed a half-page in word format.
  • Figures must be high resolution image files (jpeg, png, tif) with 300 dpi or higher.
  • Figure size should be at least 5 inches wide.
  • Colour is allowed.
  • Avoid using tables / figures that have been published before; permission will be required.

The top 50 accepted abstracts will be published in Journal of Immunotherapy and Precision Oncology alongside the conference proceedings, and the authors will be offered an expedited review process if they choose to submit their full manuscript to JIPO.

A small number of abstracts may be selected for brief oral presentation at the conference.

A small number of travel awards will be allocated to attendees who have submitted abstracts of high quality (as decided by an abstract selection committee of clinical and preclinical researchers) and who have provided a short CV and compelling letter of support from their mentor/supervisor.

If you have any queries regarding abstract submission please contact us.

The Journal of Immunotherapy and Precision Oncology (JIPO) is a high-quality, peer-reviewed publication that appeals to a broad readership of healthcare professionals and scientists, especiallythose with an interest in oncology and immunology. The Journal publishes innovative original research articles including translational science and clinical medicine, systematic and narrative reviews, letters, case reports, and invited editorials and commentaries from experts in the field. JIPO is an open access journal published quarterly.